Page 22 - ITPS-7-2

INNOSC Theranostics and
Pharmacological Sciences Novel pharmacologic therapies for SAH

Medicine. Intensive Care Med Exp. 2022;10:42. 89. Vergouwen MD, Vermeulen M, Coert BA, et al.
Microthrombosis after aneurysmal subarachnoid
doi: 10.1186/s40635-022-00463-6
hemorrhage: An additional explanation for delayed cerebral
86. Washington CW, Derdeyn CP, Dhar R, et al. A phase ischemia. J Cereb Blood Flow Metab. 2008;28:1761-1770.
I proof-of-concept and safety trial of sildenafil to treat
cerebral vasospasm following subarachnoid hemorrhage. J doi: 10.1038/jcbfm.2008.74
Neurosurg. 2016;124:318-327. 90. Frontera JA, Claassen J, Schmidt JM, et al. Prediction of
symptomatic vasospasm after subarachnoid hemorrhage:
doi: 10.3171/2015.2.JNS142752
The modified Fisher scale. Neurosurgery. 2006;59:21-27.
87. Crowley RW, Medel R, Dumont AS, et al. Angiographic doi: 10.1227/01.neu.0000243277.86222.6c
vasospasm is strongly correlated with cerebral infarction
after subarachnoid hemorrhage. Stroke. 2011;42:919-923. 91. Macdonald RL, Kassell NF, Mayer S, et al. Clazosentan to
overcome neurological ischemia and infarction occurring
doi: 10.1161/STROKEAHA.110.597005
after subarachnoid hemorrhage (CONSCIOUS-1):
88. Suarez JI, Tarr RW, Selman WR. Aneurysmal subarachnoid Randomized, double-blind, placebo-controlled phase 2
hemorrhage. N Engl J Med. 2006;354:387-396. dose-finding trial. Stroke. 2008;39:3015-3021.
doi: 10.1056/NEJMra052732 doi: 10.1161/STROKEAHA.108.519942

Volume 7 Issue 2 (2024) 16 doi: 10.36922/itps.2019